Abstract: Neural tissue edema is treated by circulating a hyperoncotic artificial cerebrospinal fluid in the cerebrospinal fluid pathway in the vicinity of edematous tissue to cause the edematous tissue to be dehydrated due to an oncotic gradient between the hypertonic artificial cerebrospinal fluid and intracellular fluid and withdrawing the fluid from the pathway after it has been so circulated.
Abstract: The present invention relates to a method of treatment of hot flushes with a 5-HT2c receptor agonist and in particular to the use of the selective 5-HT2C receptor agonists 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine and (S)-(+)-3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy-pyrrolidine or pharmaceutically acceptable acid addition salts thereof for the manufacture of a pharmaceutical formulation adapted for the treatment of hot flushes.
Abstract: Disclosed are compositions of a novel astringent and keratolytic topical pharmaceutical base into which drugs can be incorporated such as for example an anti-pruritic drug and/or an anti-inflammatory drug.
Type:
Grant
Filed:
December 13, 2001
Date of Patent:
December 17, 2002
Assignee:
Bradley Pharmaceuticals, Inc.
Inventors:
Dileep Bhagwat, Daniel Glassman, Brad P. Glassman
Abstract: The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.
Abstract: Described is a fat or oil composition which comprises at least 35 wt. % of a diacylglycerol, the constituent fatty acids of said diacylglycerol satisfying the following equation: (an amount of a cis-form unsaturated fatty acid)/(an amount of a saturated fatty acid+an amount of a trans-form unsaturated fatty acid)≧6. Usual intake of the above-described composition as an edible oil makes it possible to reduce arteriosclerotic factors in blood, leading to the prevention of arteriosclerosis, furthermore, various degenerative diseases.
Abstract: Methods for increasing oligodendrocyte survival are disclosed. The methods of the invention are useful for the treatment of Multiple Sclerosis.
Type:
Grant
Filed:
October 8, 1999
Date of Patent:
December 10, 2002
Inventors:
L. Sai Latha Shankar, William G. Tatton, Nadine A. Tatton
Abstract: The present invention involves the identification and use of compositions for treating myeloma bone disease. The compositions inhibit proteasomal activity and decrease the activity of the transcription factor NF-&kgr;B. Assessment of a candidate compound for its ability to inhibit production or activity of proteasomal enzymes or NF-&kgr;B provides a useful means to identify agents to treat myeloma bone disease.
Abstract: The present invention provides novel pharmaceutical compositions comprising aminoalkyl phosphorothioate compounds in combination with surfactants, hydrotropes and chelating agents. The compositions are well-suited for subcutaneous administration.
Abstract: A calcium formate composition for oral administration to an individual for the purpose of inhibiting gastrointestinal absorption of phosphorus is disclosed. A method of inhibiting gastrointestinal absorption of phosphorus, comprising administering orally the composition, preferably close in time to food and beverage consumption is also disclosed.
Abstract: Use of a compound of formula I
wherein
R1 is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and
each of R2, R3, R4 and R5, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form,
in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.
Type:
Grant
Filed:
July 3, 2001
Date of Patent:
November 26, 2002
Assignee:
Novartis AG
Inventors:
Sylvain Cottens, Robert Paul Hof, Roland Wenger
Abstract: A patient with an inflammatory disease of the head and neck is treated with a therapeutic amount of a selective inhibitor of cyclooxygenase-2 or a cyclooxygenase-2 inhibitor from a natural source. In one embodiment, a patient with a sore throat caused by tonsillitis or pharyngitis is treated with the topical application of a cyclooxygenase-2 inhibitor from a natural source. In other embodiments, patients with sore throat caused by tonsillitis or pharyngitis or a patient with sinusitis are treated by systemic administration of a selective inhibitor of cyclooxygenase-2. In another embodiment, a patient with periodontitis is treated by administration of a cyclooxygenase-2 inhibitor from a natural source.
Abstract: Method for the treatment of tumors in the liver of a subject wherein a pharmaceutically effective amount of at least one vitamin D compound selected from vitamin D, a precursor of vitamin D or a metabolite or analog thereof, is administered to the subject. The method involves regional delivery of the vitamin D compound to the liver, for example by intraarterial infusion to the hepatic artery. Compositions are also provided for use in such treatment.
Abstract: Compositions comprising antimuscarinic compounds that have been modified to render them substantially irreversible, such as by quaternization of the heterocyclic ring nitrogen, have improved properties when administered intravesically for treatment of bladder diseases, particularly urinary incontinence. Pharmaceutical compositions and methods of treatment using these improved compounds or improved routes of administration re disclosed.
Abstract: Arylalkanoylpyridazine derivatives of the formula I
and the physiologically acceptable salts thereof in which R1, R2, R3, R4, Q and B have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases and AIDS.
Type:
Grant
Filed:
March 15, 2000
Date of Patent:
November 12, 2002
Assignee:
Merck Patent Gesellschaft Mit Beschraenkter Haftung
Inventors:
Jonas Rochus, Norbert Beier, Franz-Werner Kluxen, Michael Wolf
Abstract: The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:
Type:
Grant
Filed:
May 6, 1999
Date of Patent:
November 12, 2002
Assignee:
Wyeth
Inventors:
James Harrison Pickar, Barry Samuel Komm
Abstract: A method of and composition for diminishing multiple sclerosis symptoms are disclosed. In one embodiment, the method comprises the step of administrating an amount of calcium and a vitamin D compound effect to diminish multiple sclerosis symptoms. In another embodiment, the invention is a pharmaceutical composition comprising an amount of calcium and vitamin D compound effective to diminish multiple sclerosis symptoms.
Type:
Grant
Filed:
July 8, 1999
Date of Patent:
November 12, 2002
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Hector F. DeLuca, Margherite T. Cantorna, Jean Humpal-Winter
Abstract: Methods and compositions are disclosed utilizing the optically pure S(−) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the administration of the racemic mixture of amlodipine. The S(−) isomer of amlodipine is also useful for the treatment of angina and such other conditions as may be related to the activity of S(−) amlodipine as a calcium channel antagonist without the concomitant liability of adverse effects associated with the racemic mixture of amlodipine.
Abstract: An L-carnitine agent has an indispensable function in the body and utility as a material for pharmaceutical agents or food and drink. By subjecting milk or modified milk products of mammals from which casein is removed, to the treatment of desalting and partial removal of lactose followed by drying, L-carnitine content, lactose content, and ash content are adjusted to 0.1˜100 mmol/100 g, 20˜95 g/100 g, and 5 g/100 g or less, respectively.
Abstract: Described are methods for treating, preventing, or reducing the risk of the onset of Alzheimer's disease by administering a therapeutically effective amount of an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (“HMG CoA reductase inhibitor”) to a patient who is at risk for a coronary or cerebrovascular event or at risk for Alzheimer's disease.
Abstract: Methods and formulations for minimizing excess collagen are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others.
Type:
Grant
Filed:
March 30, 2000
Date of Patent:
October 29, 2002
Assignee:
Vivus, Inc.
Inventors:
Virgil A. Place, Leland F. Wilson, Paul C. Doherty, Jr., Mark S. Hanamoto, Alfred P. Spivack, Neil Gesundheit, Sean R. Bennett